Short answer
Moderna (MRNA) filed an 8-K current report with the SEC on July 31, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Moderna released financial results for Q2 2026, ended June 30, 2026.
Moderna 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Moderna released financial results for Q2 2026, ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the detailed results
- Information furnished under Item 2.02, not deemed filed under Exchange Act Section 18
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $145M, up from $142M, while net loss improved 5% to $782M and EPS to $(1.97)
- 2026 revenue target remains up to 10% growth, with approximately 55% of second-half revenue expected in Q3
- 2026 R&D outlook reduced to $2.9B from $3.0B, supporting projected year-end cash of $4.7B–$5.2B
- Cash and investments fell to $6.9B from $7.5B, with $950M litigation settlement paid in July
- mRNA-1403 norovirus vaccine missed interim early-success criteria, creating additional development risk despite potential mFLUSIVA approval August 5
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Moderna 8-K filings
Get the next MRNA 8-K as it lands
Follow MRNA for push alerts, or ask the research agent what this filing means.